San Diego, USA – October 15, 2015 /PressCable/ — Kalos is globally known for their pioneering approach to cancer treatment by developing peptides made primarily in the heart, as a cytostatic therapeutic for treating aggressive cancers by engaging known pathway receptors more efficiently without the side effects associated with chemotherapeutic or small molecule compounds. Therefore the announcement of their lead drug candidate, KTH-222, has been hailed as a breakthrough cancer drug capable of besting current treatments in terms of efficacy and simultaneously avoiding the tremendous cascade of side effects typically associated with chemotherapy.
Lead Drug Candidate 1: KTH-222, Pancreatic Cancer
“Based on extensive work with human cancer cells lines and, more recently, models of human cancer, we have selected KTH-222 for clinical development to treat pancreatic cancer. The data indicates that KTH-222 may be more effective for treating this disease than current therapies while producing fewer adverse side effects” stated CSO Dr. Michael Kozlowski.
Even without optimizing the dose or the dosing regimen, KTH-222 produced a reduction in tumor growth and has now surpassed that of the standard of care, gemcitabine (Gem), which optimally dosed.
Read more: http://www.cbs19.tv/story/30265454/kalos-therapeutics-announces-selection-of-new-lead-drug-candidates